-
Product Insights
NewNet Present Value Model: MorphoSys AG’s Pelabresib
Empower your strategies with our Net Present Value Model: MorphoSys AG's Pelabresib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – MorphoSys AG
MorphoSys AG (Morphosys) is commercial-stage biopharmaceutical company that develop monoclonal antibodies for therapeutic and research applications, with focused on the treatment of cancer and autoimmune diseases. The company's product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. Morphosys also...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Skin Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Skin Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Skin Inflammation Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Ulcerative Colitis Drug Details: Guselkumab (CNTO-1959, Tremfya, Tremfya One-Press)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Guselkumab in Erosive Oral Lichen Planus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Guselkumab in Erosive Oral Lichen Planus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Guselkumab in Erosive Oral Lichen Planus Drug Details: Guselkumab...
-
Thematic Analysis
NewPharma M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Pharma Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XL-888 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XL-888 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XL-888 in Colorectal Cancer Drug Details: XL-888 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pelabresib in Essential Thrombocythemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Essential Thrombocythemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pelabresib in Essential Thrombocythemia Drug Details: Pelabresib (CPI-0610) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tulmimetostat in Sezary Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Sezary Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tulmimetostat in Sezary Syndrome Drug Details: Tulmimetostat is under development for...